Equity Overview
Price & Market Data
Price: $7.55
Daily Change: -$0.42 / 5.56%
Daily Range: $7.55 - $7.97
Market Cap: $217,937,536
Daily Volume: 409,681
Performance Metrics
1 Week: 6.97%
1 Month: 5.50%
3 Months: 15.86%
6 Months: -55.82%
1 Year: -54.67%
YTD: 25.12%
Company Details
Employees: 176
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.